Alzamend Neuro Inc. Reports No Revenue for Quarter Ending July 31, 2025; Net Loss Per Share at $1.28

Reuters09-11

<a href="https://laohu8.com/S/ALZN">Alzamend Neuro</a> Inc. Reports No Revenue for Quarter Ending July 31, 2025; Net Loss Per Share at $1.28

Alzamend Neuro Inc. released its quarterly financial results for the period ending July 31, 2025. The company did not report any revenue for this quarter, consistent with the same period in 2024, as its product candidates AL001 and ALZN002 are still in the clinical stage of development. The net loss per common share was reported at $1.28, based on a basic and diluted weighted average of 2.1 million common shares outstanding. This is a decrease compared to a net loss per common share of $11.42 in the previous period, which was based on a lower average of 85,314 common shares outstanding. The company does not anticipate generating revenue in the foreseeable future as its product candidates require extensive development, regulatory approval, and significant investment before they can be marketed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alzamend Neuro Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001214659-25-013609), on September 10, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2566982139?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-11 04:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2566982139","market":"us","top_or_hot":-1,"title":"Alzamend Neuro Inc. Reports No Revenue for Quarter Ending July 31, 2025; Net Loss Per Share at $1.28","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ALZN\">Alzamend Neuro</a> Inc. Reports No Revenue for Quarter Ending July 31, 2025; Net Loss Per Share at $1.28\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Alzamend Neuro Inc. released its quarterly financial results for the period ending July 31, 2025. The company did not report any revenue for this quarter, consistent with the same period in 2024, as its product candidates AL001 and ALZN002 are still in the clinical stage of development. The net loss per common share was reported at $1.28, based on a basic and diluted weighted average of 2.1 million common shares outstanding. This is a decrease compared to a net loss per common share of $11.42 in the previous period, which was based on a lower average of 85,314 common shares outstanding. The company does not anticipate generating revenue in the foreseeable future as its product candidates require extensive development, regulatory approval, and significant investment before they can be marketed.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alzamend Neuro Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001214659-25-013609), on September 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alzamend Neuro Inc. Reports No Revenue for Quarter Ending July 31, 2025; Net Loss Per Share at $1.28</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlzamend Neuro Inc. Reports No Revenue for Quarter Ending July 31, 2025; Net Loss Per Share at $1.28\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-11 04:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ALZN\">Alzamend Neuro</a> Inc. Reports No Revenue for Quarter Ending July 31, 2025; Net Loss Per Share at $1.28\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Alzamend Neuro Inc. released its quarterly financial results for the period ending July 31, 2025. The company did not report any revenue for this quarter, consistent with the same period in 2024, as its product candidates AL001 and ALZN002 are still in the clinical stage of development. The net loss per common share was reported at $1.28, based on a basic and diluted weighted average of 2.1 million common shares outstanding. This is a decrease compared to a net loss per common share of $11.42 in the previous period, which was based on a lower average of 85,314 common shares outstanding. The company does not anticipate generating revenue in the foreseeable future as its product candidates require extensive development, regulatory approval, and significant investment before they can be marketed.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alzamend Neuro Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001214659-25-013609), on September 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALZN","symbol_name":"Alzamend Neuro, Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250910:nNDL3M07zn:1","article_id":"2566982139","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2566982139","pubTimestamp":1757536315,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Alzamend Neuro Inc. released its quarterly financial results for the period ending July 31, 2025. The company did not report any revenue for this quarter, consistent with the same period in 2024, as its product candidates AL001 and ALZN002 are still in the clinical stage of development. The net loss per common share was reported at $1.28, based on a basic and diluted weighted average of 2.1 million common shares outstanding. This is a decrease compared to a net loss per common share of $11.42 in the previous period, which was based on a lower average of 85,314 common shares outstanding. The company does not anticipate generating revenue in the foreseeable future as its product candidates require extensive development, regulatory approval, and significant investment before they can be marketed.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ALZN":"Alzamend Neuro, Inc"},"translate_title":"Alzamend Neuro Inc.报告截至2025年7月31日的季度没有收入；每股净亏损1.28美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALZN":0.9},"content_text":"Alzamend Neuro Inc. Reports No Revenue for Quarter Ending July 31, 2025; Net Loss Per Share at $1.28\n    \n\n        Alzamend Neuro Inc. released its quarterly financial results for the period ending July 31, 2025. The company did not report any revenue for this quarter, consistent with the same period in 2024, as its product candidates AL001 and ALZN002 are still in the clinical stage of development. The net loss per common share was reported at $1.28, based on a basic and diluted weighted average of 2.1 million common shares outstanding. This is a decrease compared to a net loss per common share of $11.42 in the previous period, which was based on a lower average of 85,314 common shares outstanding. The company does not anticipate generating revenue in the foreseeable future as its product candidates require extensive development, regulatory approval, and significant investment before they can be marketed.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alzamend Neuro Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001214659-25-013609), on September 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2566982139","isCrawlerRequest":true}